■基底细胞癌(BCC)是全球最常见的皮肤癌类型。BCC的发病机制涉及各种环境和遗传因素之间的相互作用。据信趋化因子通过产生自分泌和旁分泌信号效应在调节癌症生长中起重要作用。本研究是为了阐明趋化因子的表达,CXCL11及其受体CXCR3,以及它们与BCC各种亚型中肿瘤细胞和肿瘤周围基质的相互作用。
■本研究的目的是评估趋化因子CXCL11及其受体CXCR3在BCC各种亚型中的免疫组织化学表达。
■该研究包括40例经组织病理学证实的BCC。注意到各种肿瘤亚型的临床和组织病理学特征。使用针对CXCL11和CXCR3的抗体进行免疫组织化学,并根据免疫组织化学表达将其分为0、1和2。
■研究参与者的中位年龄为65.0±12.2岁,男女比例为1.5:1。最常见的部位是脸,其次是脖子,头皮,和回来。纳入研究的肿瘤亚型为结节型(n=20),色素(n=8),渗透(n=5),表面(n=4),和腺样体(n=3)。关于免疫组织化学,CXCR3表达在34例(85%)中,间质炎性细胞免疫阳性29例(72.5%),肿瘤细胞免疫阳性5例(12.5%)。CXCL11在36例(90%)中表达,在间质和肿瘤中有弱表达18例,其余18例强表达。在单个亚型中,肿瘤细胞和肿瘤周围间质中CXCR3和CXCL11的免疫阳性较高,渗透,和色素亚型,与腺样体和浅表亚型相比。
■我们的研究表明趋化因子CXCL11及其受体CXCR3在BCC的肿瘤细胞和肿瘤周围基质中的表达增强。这种表达在侵袭性亚型的肿瘤细胞中更高,即结节,渗透,和色素类型。这表明涉及CXCR3和CXCL11的受体配体通路在BCC的发病机制中起关键作用。阻断该途径可能导致肿瘤生长的抑制。因此,这些趋化因子可作为未来开发针对BCC的新型治疗方案的潜在靶点.
UNASSIGNED: Basal cell carcinoma (BCC) is the most common type of skin cancer worldwide. The pathogenesis of BCC involves interplay between various environmental and genetic factors. It is believed that chemokines play a significant role in the modulation of cancer growth by generating autocrine and paracrine signaling effects. The present study was conducted to elucidate the expression of chemokine,
CXCL11, and its receptor CXCR3, and their interaction with tumor cells and peri-tumoral stroma in various subtypes of BCC.
UNASSIGNED: The aim of this study was to evaluate the immunohistochemical expression of chemokine CXCL11 and its receptor CXCR3 in various subtypes of BCC.
UNASSIGNED: The study included 40 cases of histopathologically confirmed BCC. Clinical and histopathological features of various tumor subtypes were noted. Immunohistochemistry was performed using antibodies against
CXCL11 and CXCR3, and these were assigned scores 0, 1, and 2 on the basis of immunohistochemical expression.
UNASSIGNED: The median age of study participants was 65.0 ± 12.2 years with a male-to-female ratio of 1.5:1. The most common site was face, followed by neck, scalp, and back. The tumor subtypes included in the study were nodular (n = 20), pigmented (n = 8), infiltrating (n = 5), superficial (n = 4), and adenoid (n = 3). On immunohistochemistry, CXCR3 expression was seen in 34 (85%) cases with stromal inflammatory cells immunopositivity in 29 (72.5%) cases and tumor cells immunopositivity in 5 (12.5%) cases.
CXCL11 expression was seen in 36 (90%) cases with weak expression in stroma and tumor in 18 cases and strong expression in the rest 18 cases. In individual subtypes, higher immunopositivity for CXCR3 and
CXCL11 in tumor cells and peri-tumoral stroma was seen for nodular, infiltrating, and pigmented subtypes, compared to adenoid and superficial subtypes.
UNASSIGNED: Our study shows the enhanced expression of chemokine CXCL11 and its receptor CXCR3 in tumor cells and peri-tumoral stroma of BCC. This expression is greater in tumor cells of aggressive subtypes, i.e. nodular, infiltrating, and pigmented types. This suggests that receptor ligand pathway involving CXCR3 and
CXCL11 plays a key role in pathogenesis of BCC, and blocking this pathway may result in inhibition of tumor growth. Thus, these chemokines may serve as future potential targets in developing novel therapeutic regimens against BCC.